Cost-effectiveness of cilostazol, naftidrofuryl oxalate, and pentoxifylline for the treatment of intermittent claudication in people with peripheral arterial disease

Angiology

Volumn 65, Issue 3, 2014, Pages 190-197

  Meng, Yang ^a   Squires, Hazel ^a   Stevens, John W ^a   Simpson, Emma ^a   Harnan, Sue ^a   Thomas, Steve ^a   Michaels, Jonathan ^a   Stansby, Gerard ^b   O'Donnell, Mark E ^c  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c ROYAL VICTORIA HOSPITAL   (United Kingdom)

Author keywords

cilostazol; cost effectiveness analysis; intermittent claudication; naftidrofuryl oxalate; pentoxifylline; peripheral arterial disease

Indexed keywords

CILOSTAZOL; NAFTIDROFURYL OXALATE; PENTOXIFYLLINE;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG COST; HUMAN; INTERMITTENT CLAUDICATION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; SENSITIVITY ANALYSIS;

CILOSTAZOL; COST-EFFECTIVENESS ANALYSIS; INTERMITTENT CLAUDICATION; NAFTIDROFURYL OXALATE; PENTOXIFYLLINE; PERIPHERAL ARTERIAL DISEASE;

COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; HUMANS; INTERMITTENT CLAUDICATION; MARKOV CHAINS; NAFRONYL; PENTOXIFYLLINE; PERIPHERAL ARTERIAL DISEASE; TETRAZOLES; VASODILATOR AGENTS;

EID: 84893602584     PISSN: 00033197     EISSN: 19401574     Source Type: Journal    
DOI: 10.1177/0003319712474335     Document Type: Article

References (26)

1. Norgren L, Hiatt WR, Dormandy JA, et al. Inter-society consensus for the management of peripheral arterial disease (TASC II). Intl Angiol. 2007 ; 26 (2). 82-157
2. Pell JP.. Impact of intermittent claudication on quality of life. The Scottish vascular audit group. Eur J Vasc Endovasc. 1995 ; 9 (4). 469-472
3. Breek JC, Hamming JF, De VJ, et al. Quality of life in patients with intermittent claudication using the World Health Organisation (WHO) questionnaire. Eur J Vasc Endovasc. 2001 ; 21 (2). 118-122
4. Fowkes FGR, Housley E, Cawood E, et al. Edinburgh artery study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol. 1991 ; 20 (2). 384-392
5. Squires H, Simpson E, Meng Y, et al. Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease. Health Technol Asses. 2011 ; 15 (40). i - 210
6. Guest JF, Davie AM, Clegg JP. Cost effectiveness of cilostazol compared with naftidrofuryl and pentoxifylline in the treatment of intermittent claudication in the UK. Curr Med Res Opin. 2005 ; 21 (6). 817-826
7. O'Donnell ME, Badger SA, Sharif MA, et al. The vascular and biochemical effects of cilostazol in patients with peripheral arterial disease. J Vasc Surg. 2009 ; 49 (5). 1226-1234
8. Kieffer E, Bahnini A, Mouren X, Gamand S. A. new study demonstrates the efficacy of naftidrofuryl in the treatment of intermittent claudication. Findings of the Naftidrofuryl Clinical Ischemia Study (NCIS). Int Angiol. 2001 ; 20 (1). 58-65
9. Hiatt WR, Money SR, Brass EP. Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects). J Vasc Surg. 2008 ; 47 (2). 330-336
10. Unit Costs of Health and Social Care 2009. London, England: PSSRU ; 2009 :
11. Guide to the Methods of Technology Appraisal. London, England: NICE ; 2008 :
12. Stevens J, Emma S, Harnan S, et al. Efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication in patients with peripheral arterial disease: systematic review and evidence synthesis. Br J Surg. 2012 ; 99: 1630-1638
13. Beebe HG, Dawson DL, Cutler BS, et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Arch Intern Med. 1999 ; 159 (17). 2041-2050
14. Ara R, Brazier J. Deriving an algorithm to convert the eight mean SF-36 dimension scores into a mean EQ-5D preference-based score from published studies (where patient level data are not available). Value Health. 2008 ; 11 (7). 1131-1143
15. Ara R, Brazier J. Populating an economic moel with health state utility values: moving towards better practice. Value Health. 2010 ; 13 (5). 509-518
16. O'Donnell ME, Badger SA, Sharif MA, et al. The vascular and biochemical effects of cilostazol in diabetic patients with peripheral arterial disease. Vasc Endovasc Surg. 2009 ; 43 (2). 132-143
17. Dawson DL, Cutler BS, Hiatt WR, et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med. 2000 ; 109 (7). 523-530
18. Adhoute G, Bacourt F, Barral M, et al. Naftidrofuryl in chronic arterial disease. Results of a six month controlled multicenter study using Naftidrofuryl tablets 200 mg. Angiology. 1986 ; 37 (3 pt 1). 160-167
19. Otsuka Pharmaceutical Submission to NICE: Cilostazol for the symptomatic treatment of intermittent claudication secondary to peripheral arterial disease.. 2010 ;:
20. Mid-2009 Population Estimates: England and Wales; Estimated Resident Population by Single Year of Age and Sex. London, UK: ONS ; 2010 :
21. Heald CL, Fowkes FGR, Murray GD, Price JF. Risk of mortality and cardiovascular disease associated with the ankle-brachial index: Systematic review. Atherosclerosis. 2006 ; 189 (1). 61-69
22. NHS Drug Tariff. Drug tariff. October 2010. URL:http://www.ppa.org.uk/ edt/October-2012/mindex.htm.
23. NHS Reference Costs 2008-2009. London, UK: DoH ; 2010 :
24. Diagnosis and Management of Peripheral Arterial Disease. A National Clinical Guideline. Edinburgh, Scotland: SIGN ; 2006 :
25. Spengel F, Clement D, Boccalon H, et al. Findings of the naftidrofuryl in quality of life (NIQOL) European study program. Int Angiol. 2002 ; 21 (1). 20-27
26. NICE Technology Appraisal Guidance 223: Cilostazol, Naftidrofuryl Oxalate, Pentoxifylline and Inositol Nicotinate for the Treatment of Intermittent Claudication in People with Peripheral Arterial Disease. London, UK: NICE ; 2011 :